以组学为基础的临床试验市场：按阶段、研究设计、适应症 - 2023-2030 年全球预测

全球基于组学的临床试验市场预计将在 2023 年大幅成长，达到 301 亿美元，年复合成长率为 8.32%，预计到 2030 年将达到惊人的 529.2 亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球组学临床试验市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.基于组学的临床试验的全球市场规模和预测是多少？

2.在预测期内，COVID-19对全球组学临床试验市场的阻碍因素与影响为何？

3. 在预测期内，全球基于组学的临床试验市场需要投资哪些产品/细分市场/应用/领域？

4. 全球组学临床试验市场的竞争策略为何？

5. 全球组学临床试验市场的技术趋势和法律规范是什么？

6. 全球基于组学的临床试验市场主要供应商的市占率是多少？

7. 哪些型态和策略措施被认为适合进入基于组学的临床试验的全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 加大医药研发部门投入
    • 全球各种慢性病的罹患率和负担正在增加。
    • 日益关注个人化医疗和肿瘤学临床临床实验
  • 抑制因素
    • 基于组学的临床试验产品价格昂贵
  • 机会
    • 提高消费者意识并采用多组学解决方案
    • 全球合併活动数量激增
  • 任务
    • 有效资料分析的挑战
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章以组学为基础的临床试验市场分阶段

• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段

第7章研究设计的基于组学的临床试验市场

• 扩大访问研究
• 干预研究
• 观察性研究

第8章以组学为基础的临床试验市场（按适应症）

• 心臟病学
• 中枢神经系统疾病
• 遗传疾病
• 免疫学
• 肿瘤学
• 呼吸系统疾病
• 皮肤病

第9章美洲组学临床试验市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第10章亚太组学临床试验市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第11章欧洲、中东和非洲基于组学的临床试验市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第12章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

• 讨论指南
• 关于许可证和定价

The Global Omics-Based Clinical Trials Market is forecasted to grow significantly, with a projected USD 30.10 billion in 2023 at a CAGR of 8.32% and expected to reach a staggering USD 52.92 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Omics-Based Clinical Trials Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Omics-Based Clinical Trials Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV. The Phase II is projected to witness significant market share during forecast period.

Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies. The Expanded Access Studies is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases. The Cardiology is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Omics-Based Clinical Trials Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Omics-Based Clinical Trials Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Omics-Based Clinical Trials Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Omics-Based Clinical Trials Market?

4. What is the competitive strategic window for opportunities in the Global Omics-Based Clinical Trials Market?

5. What are the technology trends and regulatory frameworks in the Global Omics-Based Clinical Trials Market?

6. What is the market share of the leading vendors in the Global Omics-Based Clinical Trials Market?

7. What modes and strategic moves are considered suitable for entering the Global Omics-Based Clinical Trials Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Omics-Based Clinical Trials Market, by Phase, 2022 vs 2030
• 4.3. Omics-Based Clinical Trials Market, by Study Design, 2022 vs 2030
• 4.4. Omics-Based Clinical Trials Market, by Indication, 2022 vs 2030
• 4.5. Omics-Based Clinical Trials Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising investment in the pharmaceutical research and development sector
    • 5.1.1.2. Increasing prevalence and burden of various chronic diseases globally
    • 5.1.1.3. Growing focus on personalized medicine and oncology trials
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of omics-based clinical trials products
  • 5.1.3. Opportunities
    • 5.1.3.1. Upsurging consumer awareness and adoption of multi-omics solutions
    • 5.1.3.2. Proliferation in the number of amalgamation activities across the globe
  • 5.1.4. Challenges
    • 5.1.4.1. Issues relating to effective data analysis
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Omics-Based Clinical Trials Market, by Phase

• 6.1. Introduction
• 6.2. Phase I
• 6.3. Phase II
• 6.4. Phase III
• 6.5. Phase IV

7. Omics-Based Clinical Trials Market, by Study Design

• 7.1. Introduction
• 7.2. Expanded Access Studies
• 7.3. Interventional Studies
• 7.4. Observational Studies

8. Omics-Based Clinical Trials Market, by Indication

• 8.1. Introduction
• 8.2. Cardiology
• 8.3. CNS Diseases
• 8.4. Genetic Diseases
• 8.5. Immunology
• 8.6. Oncology
• 8.7. Respiratory Diseases
• 8.8. Skin Diseases

9. Americas Omics-Based Clinical Trials Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Omics-Based Clinical Trials Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Omics-Based Clinical Trials Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. OMICS-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2022 VS 2030
• FIGURE 3. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2030 (%)
• FIGURE 5. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2022 VS 2030 (%)
• FIGURE 6. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
• FIGURE 7. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 8. OMICS-BASED CLINICAL TRIALS MARKET DYNAMICS
• FIGURE 9. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 17. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. OMICS-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 5. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 10. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 33. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 50. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 53. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 105. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 117. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 120. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 149. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 150. OMICS-BASED CLINICAL TRIALS MARKET LICENSE & PRICING